John Parkinson

A small study is reporting very few adverse effects and low rates of COVID-19 transmission rates from mother to baby.

Medication shown to inhibit virus from infecting cells and replicating.

A pediatric cardiologist discusses the specifics of a case study, the importance of adaptability, and how her healthcare system has developed treatment protocols in these cases.

Scans typically used to diagnose strokes are showing physical signs in the lungs that identify COVID-19.

Eli Lilly’s investigational therapy, LY-CoV555, was shown to be well-tolerated and met its primary endpoint for one of its doses.

A survey from The Ohio State University shows a majority of Americans would get an approved vaccine.

In a newly published paper, investigators believe the novel virus will follow similar patterns to seasonal viruses like influenza.

An examination of ventilator patients found a significant number of them could suffer from a variety of life-long injuries.

A clinical-stage immunology company has an investigational therapy looking to target the tumor necrosis factor cytokine.

The investigational vaccine was regarded as well-tolerated and elicited an immune response.

An examination of a patient presenting with the condition in the early days of the pandemic without the access to current care protocols.

This test simultaneously detects and differentiates between SARS-CoV-2, influenza A and B.

If phase 1/2 data is positive, the companies plan to move into phase 3 by December.

The federal agency sent a checklist and priority list to all 50 states and 5 large American cities as it prepares for vaccine approval.

The test designed to detect SARS-CoV-2 will be available in Europe later this month and provides results in 15 minutes.

The company is recruiting up to 30000 Americans for AZD1222, its vaccine candidate, as it enters a late-stage trial.

FDA expands usage to all hospitalized COVID-19 patients.

ARCC made the announcement yesterday that the WHO African Region is free of the virus.

ViiV Healthcare’s dolutegravir/lamivudine (Dovato) may be potential treatment option for this patient population

Company says investigational therapeutic could afford at least 6 months of protection from the virus.

This could be an important feature in potential vaccine development.

Regeneron will distribute a prospective therapy in the US and Roche will be responsible for it internationally.

The IDSA recommends against its use in the hospital setting.

The vaccine candidate, BNT162b2, was well-tolerated and phase 3 enrollment is more than one-third complete.

In unexposed blood samples, investigators discovered memory helper T cells that recognize cold coronaviruses also recognized SARS-CoV-2, and may help people fight off the virus.

ViiV Healthcare’s recent FDA approval of expanding a combination antiretroviral comes on the heels of the important data from the TANGO study.

In a small study, preliminary analysis shows patients given this treatment early in hospitalization showed improvement and reduced mortality rates.

The pharmaceutical company has over 25% more US doses due to the increased anticipation of higher demand because of COVID-19.

Two Boston physicians using Interleukin-6 inhibitors report a reduction in intubation and mortality rates.

A new survey shows parents’ fears of getting kids to their providers for fear of contracting the virus.